Processa Pharmaceuticals, Inc. (PCSA) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 5, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PCSA SEC filings page.
This page shows Processa Pharmaceuticals, Inc. (PCSA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Reported earnings do not reflect operating performance: this remains a pre-revenue development business funded mainly through financing.
In FY2025, the company reported net income of$13.6M even as its operating loss was$14.0M ; the positive bottom line therefore does not describe its core activities. Operating cash flow was-$11.4M , reinforcing that reported earnings have not translated into internally generated cash, and the same disconnect persisted in FY2024.
Financing, not operations, repaired the balance sheet: FY2025 financing cash flow of
No revenue is reported across the periods, while FY2025 R&D and SG&A totaled
Financial Health Signals
Processa Pharmaceuticals, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Processa Pharmaceuticals, Inc. passes 4 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, all 2 leverage/liquidity signals pass.
For every $1 of reported earnings, Processa Pharmaceuticals, Inc. used $0.84 of operating cash (-$11.4M OCF vs $13.6M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Key Financial Metrics
Earnings & Revenue
Processa Pharmaceuticals, Inc.'s EBITDA was -$2.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 40.9% from the same quarter a year earlier. Against the prior quarter it is up 29.9%.
Processa Pharmaceuticals, Inc. reported -$3.3M in net income in Q2 2026. This represents an increase of 17.0% from the same quarter a year earlier. Against the prior quarter it is up 3.3%.
Processa Pharmaceuticals, Inc. earned -$1.19 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 7.8%.
Not reported for Q2 2026.
Cash & Balance Sheet
Processa Pharmaceuticals, Inc. held $196K in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
Processa Pharmaceuticals, Inc. invested $650K in research and development in Q2 2026. This represents a decrease of 73.4% from the same quarter a year earlier. Against the prior quarter it is down 64.1%.
Not reported for Q2 2026.
Not reported for Q2 2026.
PCSA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $650K-73.4% | $1.8M+13.9% | N/A | $1.7M-27.4% | $2.4M+41.4% | $1.6M+3.2% | N/A | $2.3M+98.6% |
| SG&A Expenses | $1.7M+12.2% | $1.5M+20.9% | N/A | $1.8M+60.7% | $1.5M+11.2% | $1.3M-1.0% | N/A | $1.1M+12.0% |
| Operating Income | -$2.3M+40.9% | -$3.3M-17.0% | N/A | -$3.5M-1.9% | -$4.0M-28.2% | -$2.8M-1.3% | N/A | -$3.4M-58.0% |
| EBITDA | -$2.3M+40.9% | -$3.3M-17.0% | N/A | -$3.5M-1.9% | -$4.0M-28.2% | -$2.8M-1.3% | N/A | -$3.4M |
| Interest Expense | $2K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$3.3M+17.0% | -$3.4M-19.1% | N/A | -$3.4M-1.5% | -$3.9M-30.7% | -$2.8M-4.0% | N/A | -$3.4M-62.6% |
| EPS (Basic) | -$1.19+81.0% | -$1.29+83.0% | -$9.95+89.4% | -$0.07+93.2% | -$6.26-519.8% | -$7.58-582.9% | -$93.65-1050.5% | -$1.03+33.1% |
| EPS (Diluted) | -$1.19 | -$1.29 | -$9.95 | -$0.07 | -$6.26 | -$7.58 | -$93.65 | -$1.03 |
| Diluted Shares (Avg) | 3M | 3M | N/A | 48M | 628,796 | 373,967 | N/A | 3M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
PCSA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.1M-74.7% | $4.5M-6.0% | $7.8M+142.0% | $7.6M+53.5% | $8.2M+7.6% | $4.8M-51.6% | $3.2M-44.2% | $4.9M-38.9% |
| Current Assets | $2.1M-71.1% | $1.9M-48.4% | $5.7M+201.8% | $6.6M+36.1% | $7.2M-4.3% | $3.8M-61.7% | $1.9M-66.6% | $4.8M-38.8% |
| Cash & Equivalents | $196K-97.2% | $1.7M-41.6% | $5.5M+364.8% | $6.3M+118.2% | $6.9M+24.5% | $2.9M-67.5% | $1.2M-74.7% | $2.9M-57.9% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $2.4M+15.1% | $2.0M+54.3% | $2.2M+45.9% | $1.8M+43.4% | $2.1M+31.5% | $1.3M+20.9% | $1.5M+92.2% | $1.2M+33.5% |
| Current Liabilities | $2.4M+15.1% | $2.0M+54.3% | $2.2M+45.9% | $1.8M+43.6% | $2.1M+33.7% | $1.3M+26.9% | $1.5M+109.8% | $1.2M+47.6% |
| Non-Current Liabilities | $0 | $0 | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $487-99.3% | $2K-97.6% |
| Total Equity | -$317K-105.2% | $2.5M-28.0% | $5.6M+228.8% | $5.8M+56.8% | $6.1M+1.4% | $3.5M-60.3% | $1.7M-66.0% | $3.7M-48.1% |
| Retained Earnings | -$107.4M-14.3% | -$104.2M-15.7% | -$100.8M-15.6% | -$97.4M-15.3% | -$94.0M-15.9% | -$90.1M-15.3% | -$87.2M-15.7% | -$84.5M-15.8% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
PCSA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.0M+12.1% | -$3.6M-31.5% | -$2.9M-29.0% | -$3.5M+3.3% | -$2.3M+32.1% | -$2.7M-33.2% | -$2.2M-5.8% | -$3.6M-104.6% |
| Depreciation & Amortization | $3010.0% | $3010.0% | $3010.0% | $301+48.3% | $301+116.5% | $301+116.5% | $301+115.0% | $203 |
| Stock-Based Compensation | $92K-54.7% | $96K-57.9% | N/A | $303K+96.5% | $203K+33.2% | $228K+35.8% | N/A | $154K+7.9% |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | $0 | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | -$2.2M-5.8% | N/A |
| Investing Cash Flow | $186K | -$500K | N/A | N/A | N/A | N/A | $0 | N/A |
| Financing Cash Flow | $315K-95.0% | $245K-94.5% | $3.0M+444.0% | $2.9M+208.4% | $6.3M+184925.8% | $4.4M-29.2% | $548K+1889.1% | $926K+1856.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
PCSA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | N/A | -132.9%-52.5pp | N/A | -58.9%+32.1pp | -64.4%-14.4pp | -80.4%-49.7pp | N/A | -91.0%-61.9pp |
| Return on Assets | -157.8%-109.7pp | -74.7%-15.8pp | N/A | -45.3%+23.2pp | -48.1%-8.5pp | -58.9%-31.5pp | N/A | -68.5%-42.7pp |
| Current Ratio | 0.87-2.6x | 0.98-2.0x | 2.54+1.3x | 3.76-0.2x | 3.45-1.4x | 2.93-6.8x | 1.23-6.5x | 3.97-5.6x |
| Debt-to-Equity | N/A | 0.78+0.4x | 0.40-0.5x | 0.300.0x | 0.34+0.1x | 0.36+0.2x | 0.90+0.7x | 0.33+0.2x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Processa Pharmaceuticals, Inc. PCSA | FY2025 | N/A | $13.6M | N/A | $4.2M | — |
| Bolt Biotherapeutics, Inc. BOLT | FY2025 | $7.7M | -$33.4M | N/A | $6.6M | 64/100 |
| Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock CYCCP | FY2025 | $747K | $3.0M | N/A | $9.6M | — |
| IN8bio, Inc. INAB | FY2025 | N/A | -$19.4M | N/A | $13.8M | — |
| Dogwood Therapeutics, Inc. DWTX | FY2025 | N/A | -$34.3M | N/A | $49.6M | — |
| TransCode Therapeutics, Inc. RNAZ | FY2025 | N/A | -$34.7M | N/A | $26.6M | — |
Where Processa Pharmaceuticals, Inc. Ranks
Frequently Asked Questions
Is Processa Pharmaceuticals, Inc. profitable?
Yes, Processa Pharmaceuticals, Inc. (PCSA) reported a net income of $13.6M in fiscal year 2025.
What is Processa Pharmaceuticals, Inc.'s EBITDA?
Processa Pharmaceuticals, Inc. (PCSA) had EBITDA of -$14.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Processa Pharmaceuticals, Inc.'s return on equity (ROE)?
Processa Pharmaceuticals, Inc. (PCSA) has a return on equity of 243.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Processa Pharmaceuticals, Inc.'s operating cash flow?
Processa Pharmaceuticals, Inc. (PCSA) recorded an outflow of $11.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Processa Pharmaceuticals, Inc.'s total assets?
Processa Pharmaceuticals, Inc. (PCSA) had $7.8M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Processa Pharmaceuticals, Inc. spend on research and development?
Processa Pharmaceuticals, Inc. (PCSA) invested $7.8M in research and development during fiscal year 2025.
What is Processa Pharmaceuticals, Inc.'s current ratio?
Processa Pharmaceuticals, Inc. (PCSA) had a current ratio of 2.54 as of fiscal year 2025, which is generally considered healthy.
What is Processa Pharmaceuticals, Inc.'s debt-to-equity ratio?
Processa Pharmaceuticals, Inc. (PCSA) had a debt-to-equity ratio of 0.40 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Processa Pharmaceuticals, Inc.'s return on assets (ROA)?
Processa Pharmaceuticals, Inc. (PCSA) had a return on assets of 173.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Processa Pharmaceuticals, Inc.'s P/E ratio?
Processa Pharmaceuticals, Inc. (PCSA) trades at 0.3x earnings, its market capitalization divided by net income of $13.6M net income, FY2025. The market capitalization is $4.2M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Processa Pharmaceuticals, Inc.'s price-to-sales ratio?
Processa Pharmaceuticals, Inc. (PCSA) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $4.2M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Processa Pharmaceuticals, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Processa Pharmaceuticals, Inc. (PCSA) held $5.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $11.4M over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Processa Pharmaceuticals, Inc.'s Piotroski F-Score?
Processa Pharmaceuticals, Inc. (PCSA) has a Piotroski F-Score of 4 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Processa Pharmaceuticals, Inc.'s earnings high quality?
For every $1 of reported earnings, Processa Pharmaceuticals, Inc. (PCSA) used $0.84 of operating cash (-$11.4M OCF vs $13.6M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.